| <P class=MsoNormal style="MARGIN: 2.5pt 0cm; TEXT-INDENT: 15.75pt; LINE-HEIGHT: 20pt; TEXT-ALIGN: left; mso-pagination: widow-orphan; mso-char-indent-count: 1.5; mso-line-height-rule: exactly" align=left><FONT size=3><SPAN style="FONT-FAMILY: 宋体; mso-bidi-font-size: 10.5pt; mso-font-kerning: 0pt; mso-ascii-font-family: ’Times New Roman’; mso-hansi-font-family: ’Times New Roman’; mso-bidi-font-weight: bold">欧盟批准第一制药</SPAN><SPAN lang=EN-US style="mso-bidi-font-size: 10.5pt; mso-font-kerning: 0pt; mso-bidi-font-weight: bold"><FONT face="Times New Roman">-</FONT></SPAN><SPAN style="FONT-FAMILY: 宋体; mso-bidi-font-size: 10.5pt; mso-font-kerning: 0pt; mso-ascii-font-family: ’Times New Roman’; mso-hansi-font-family: ’Times New Roman’; mso-bidi-font-weight: bold">三共公司与礼来公司联合开发的普拉格雷薄膜包衣片</SPAN><SPAN style="FONT-FAMILY: 黑体; mso-bidi-font-size: 10.5pt; mso-font-kerning: 0pt; mso-ascii-font-family: ’Times New Roman’; mso-bidi-font-weight: bold">（</SPAN><SPAN lang=EN-US style="mso-bidi-font-size: 10.5pt; mso-font-kerning: 0pt; mso-bidi-font-weight: bold"><FONT face="Times New Roman">prasugrel</FONT></SPAN><SPAN style="FONT-FAMILY: 宋体; mso-bidi-font-size: 10.5pt; mso-font-kerning: 0pt; mso-ascii-font-family: ’Times New Roman’; mso-hansi-font-family: ’Times New Roman’; mso-bidi-font-weight: bold">，</SPAN><SPAN lang=EN-US style="mso-bidi-font-size: 10.5pt; mso-font-kerning: 0pt; mso-bidi-font-weight: bold"><FONT face="Times New Roman">Efient</FONT></SPAN><SPAN style="FONT-FAMILY: 宋体; mso-bidi-font-size: 10.5pt; mso-font-kerning: 0pt; mso-ascii-font-family: ’Times New Roman’; mso-hansi-font-family: ’Times New Roman’; mso-bidi-font-weight: bold">）上市，用于预防经皮</SPAN><SPAN style="FONT-FAMILY: 宋体; mso-bidi-font-size: 10.5pt; mso-font-kerning: 0pt; mso-ascii-font-family: ’Times New Roman’; mso-hansi-font-family: ’Times New Roman’">冠状动脉介入治疗（</SPAN><SPAN lang=EN-US style="mso-bidi-font-size: 10.5pt; mso-font-kerning: 0pt"><FONT face="Times New Roman">PCI</FONT></SPAN><SPAN style="FONT-FAMILY: 宋体; mso-bidi-font-size: 10.5pt; mso-font-kerning: 0pt; mso-ascii-font-family: ’Times New Roman’; mso-hansi-font-family: ’Times New Roman’">）急性冠状动脉综合征（</SPAN><SPAN lang=EN-US style="mso-bidi-font-size: 10.5pt; mso-font-kerning: 0pt"><FONT face="Times New Roman">ACS</FONT></SPAN><SPAN style="FONT-FAMILY: 宋体; mso-bidi-font-size: 10.5pt; mso-font-kerning: 0pt; mso-ascii-font-family: ’Times New Roman’; mso-hansi-font-family: ’Times New Roman’">）患者的动脉粥样栓塞发生。本品剂量规格：普拉格雷</SPAN><SPAN lang=EN-US style="mso-bidi-font-size: 10.5pt; mso-font-kerning: 0pt"><FONT face="Times New Roman">5 mg/</FONT></SPAN><SPAN style="FONT-FAMILY: 宋体; mso-bidi-font-size: 10.5pt; mso-font-kerning: 0pt; mso-ascii-font-family: ’Times New Roman’; mso-hansi-font-family: ’Times New Roman’">片、</SPAN><SPAN lang=EN-US style="mso-bidi-font-size: 10.5pt; mso-font-kerning: 0pt"><FONT face="Times New Roman">10 mg/</FONT></SPAN><SPAN style="FONT-FAMILY: 宋体; mso-bidi-font-size: 10.5pt; mso-font-kerning: 0pt; mso-ascii-font-family: ’Times New Roman’; mso-hansi-font-family: ’Times New Roman’">片。</SPAN><FONT face="Times New Roman"><B><SPAN style="mso-bidi-font-size: 10.5pt; mso-font-kerning: 0pt"> </SPAN></B><SPAN lang=EN-US style="mso-bidi-font-size: 10.5pt; mso-font-kerning: 0pt"><?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></FONT></FONT></P><BR>
<P class=MsoNormal style="MARGIN: 2.5pt 0cm; TEXT-INDENT: 15.75pt; LINE-HEIGHT: 20pt; TEXT-ALIGN: left; mso-pagination: widow-orphan; mso-char-indent-count: 1.5; mso-line-height-rule: exactly" align=left><FONT size=3><SPAN lang=EN-US style="mso-bidi-font-size: 10.5pt; mso-font-kerning: 0pt"><SPAN style="mso-spacerun: yes"><FONT face="Times New Roman"> </FONT></SPAN></SPAN><SPAN style="FONT-FAMILY: 宋体; mso-bidi-font-size: 10.5pt; mso-font-kerning: 0pt; mso-ascii-font-family: ’Times New Roman’; mso-hansi-font-family: ’Times New Roman’">此次欧洲批准本品对医生和患者是个好消息，这是由于欧盟每年死于心脏病发作的患者多达</SPAN><SPAN lang=EN-US style="mso-bidi-font-size: 10.5pt; mso-font-kerning: 0pt"><FONT face="Times New Roman">70</FONT></SPAN><SPAN style="FONT-FAMILY: 宋体; mso-bidi-font-size: 10.5pt; mso-font-kerning: 0pt; mso-ascii-font-family: ’Times New Roman’; mso-hansi-font-family: ’Times New Roman’">万例以上。</SPAN><SPAN lang=EN-US style="mso-bidi-font-size: 10.5pt; mso-font-kerning: 0pt"><FONT face="Times New Roman">ACS</FONT></SPAN><SPAN style="FONT-FAMILY: 宋体; mso-bidi-font-size: 10.5pt; mso-font-kerning: 0pt; mso-ascii-font-family: ’Times New Roman’; mso-hansi-font-family: ’Times New Roman’">系可能威胁生命的严重疾病，<SPAN style="mso-bidi-font-weight: bold"><FONT face=宋体>本品可作为进行</FONT></SPAN></SPAN><SPAN lang=EN-US style="mso-bidi-font-size: 10.5pt; mso-font-kerning: 0pt"><FONT face="Times New Roman">PCI</FONT></SPAN><SPAN style="FONT-FAMILY: 宋体; mso-bidi-font-size: 10.5pt; mso-font-kerning: 0pt; mso-ascii-font-family: ’Times New Roman’; mso-hansi-font-family: ’Times New Roman’">的</SPAN><SPAN lang=EN-US style="mso-bidi-font-size: 10.5pt; mso-font-kerning: 0pt"><FONT face="Times New Roman">ACS</FONT></SPAN><SPAN style="FONT-FAMILY: 宋体; mso-bidi-font-size: 10.5pt; mso-font-kerning: 0pt; mso-ascii-font-family: ’Times New Roman’; mso-hansi-font-family: ’Times New Roman’">患者重要的新治疗方法。</SPAN><FONT face="Times New Roman"><SPAN style="mso-bidi-font-size: 10.5pt; mso-font-kerning: 0pt; mso-bidi-font-weight: bold"> </SPAN><SPAN lang=EN-US style="mso-bidi-font-size: 10.5pt; mso-font-kerning: 0pt"><o:p></o:p></SPAN></FONT></FONT></P><BR>
<P class=MsoNormal style="MARGIN: 2.5pt 0cm; TEXT-INDENT: 23.65pt; LINE-HEIGHT: 20pt; TEXT-ALIGN: left; mso-pagination: widow-orphan; mso-char-indent-count: 2.25; mso-line-height-rule: exactly" align=left><FONT size=3><SPAN style="FONT-FAMILY: 宋体; mso-bidi-font-size: 10.5pt; mso-font-kerning: 0pt; mso-ascii-font-family: ’Times New Roman’; mso-hansi-font-family: ’Times New Roman’; mso-bidi-font-weight: bold">普拉格雷通过抑制血小板表面特异受体（</SPAN><SPAN lang=EN-US style="mso-bidi-font-size: 10.5pt; mso-font-kerning: 0pt; mso-bidi-font-weight: bold"><FONT face="Times New Roman">P2Y12</FONT></SPAN><SPAN style="FONT-FAMILY: 宋体; mso-bidi-font-size: 10.5pt; mso-font-kerning: 0pt; mso-ascii-font-family: ’Times New Roman’; mso-hansi-font-family: ’Times New Roman’; mso-bidi-font-weight: bold">二磷酸腺苷），防止血小板凝聚（造成动脉阻塞、导致心脏病发作）来发挥作用。</SPAN><FONT face="Times New Roman"><SPAN style="mso-bidi-font-size: 10.5pt; mso-font-kerning: 0pt; mso-bidi-font-weight: bold"> </SPAN><SPAN lang=EN-US style="mso-bidi-font-size: 10.5pt; mso-font-kerning: 0pt"><o:p></o:p></SPAN></FONT></FONT></P><BR>
<P class=MsoNormal style="MARGIN: 2.5pt 0cm; TEXT-INDENT: 23.65pt; LINE-HEIGHT: 20pt; TEXT-ALIGN: left; mso-pagination: widow-orphan; mso-char-indent-count: 2.25; mso-line-height-rule: exactly" align=left><FONT size=3><SPAN style="FONT-FAMILY: 宋体; mso-bidi-font-size: 10.5pt; mso-font-kerning: 0pt; mso-ascii-font-family: ’Times New Roman’; mso-hansi-font-family: ’Times New Roman’; mso-bidi-font-weight: bold">一项大规模</SPAN><SPAN lang=EN-US style="FONT-FAMILY: 宋体; mso-bidi-font-size: 10.5pt; mso-font-kerning: 0pt; mso-ascii-font-family: ’Times New Roman’; mso-bidi-font-weight: bold">Ⅲ</SPAN><SPAN style="FONT-FAMILY: 宋体; mso-bidi-font-size: 10.5pt; mso-font-kerning: 0pt; mso-ascii-font-family: ’Times New Roman’; mso-hansi-font-family: ’Times New Roman’; mso-bidi-font-weight: bold">期临床研究显示，普拉格雷减少进行</SPAN><SPAN lang=EN-US style="mso-bidi-font-size: 10.5pt; mso-font-kerning: 0pt"><FONT face="Times New Roman">PCI</FONT></SPAN><SPAN style="FONT-FAMILY: 宋体; mso-bidi-font-size: 10.5pt; mso-font-kerning: 0pt; mso-ascii-font-family: ’Times New Roman’; mso-hansi-font-family: ’Times New Roman’">的</SPAN><SPAN lang=EN-US style="mso-bidi-font-size: 10.5pt; mso-font-kerning: 0pt"><FONT face="Times New Roman">ACS</FONT></SPAN><SPAN style="FONT-FAMILY: 宋体; mso-bidi-font-size: 10.5pt; mso-font-kerning: 0pt; mso-ascii-font-family: ’Times New Roman’; mso-hansi-font-family: ’Times New Roman’">患者<SPAN style="mso-bidi-font-weight: bold"><FONT face=宋体>重大心血管疾病的危险（按心血管疾病死亡、非致死性心脏病发作或非致死性休克的综合评判）优于</FONT></SPAN>氯吡格雷（</SPAN><SPAN lang=EN-US style="mso-bidi-font-size: 10.5pt; mso-font-kerning: 0pt"><FONT face="Times New Roman">clopidogrel</FONT></SPAN><SPAN style="FONT-FAMILY: 宋体; mso-bidi-font-size: 10.5pt; mso-font-kerning: 0pt; mso-ascii-font-family: ’Times New Roman’; mso-hansi-font-family: ’Times New Roman’">，</SPAN><SPAN lang=EN-US style="mso-bidi-font-size: 10.5pt; mso-font-kerning: 0pt"><FONT face="Times New Roman">Plavix/Iscover</FONT></SPAN><SPAN style="FONT-FAMILY: 宋体; mso-bidi-font-size: 10.5pt; mso-font-kerning: 0pt; mso-ascii-font-family: ’Times New Roman’; mso-hansi-font-family: ’Times New Roman’">）。</SPAN><SPAN style="mso-bidi-font-size: 10.5pt; mso-font-kerning: 0pt"><FONT face="Times New Roman"> <SPAN lang=EN-US><o:p></o:p></SPAN></FONT></SPAN></FONT></P> |
